Ovid Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| (in thousands) | For the Year Ended December 31, 2024 | For the Year Ended December 31, 2023 |
|---|---|---|
| Net loss | $(26,433) | $(52,339) |
| Other comprehensive income: | ||
| Cumulative translation adjustment | (42) | — |
| Unrealized gain on available-for-sale securities | 7 | 1 |
| Comprehensive loss | $(26,468) | $(52,338) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.